Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

TRI Thomson Reuters Corporation Common Shares
$110.74 -1.83% -2.06
Notify me if price changes either direction
Interactive Brokers Logotype

Buy TRI stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 51.0B
Enterprise value 54.6B
Trailing PE 30.341494
Forward PE 26.489283
PEG Ratio 0.75291855481482
Enterprise to EBITDA 26.239
Enterprise to revenue 7.403
Price to book MRQ 4.4527025
Price to sales TTM 7.214657

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 7.4B
EBITDA 3.1B
Diluted EPS TTM 3.88
Total Cash (MRQ) 705.0M
Current ratio (MRQ) 0.614
Operating Cash Flow (TTM) 2.5B

TRI trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent TRI News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.